Chemed - CHE Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHE shares.
View CHE analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1-year price objectives for Chemed's shares. Their CHE share price forecasts range from $587.00 to $587.00. On average, they expect the company's stock price to reach $587.00 in the next year. This suggests a possible upside of 10.9% from the stock's current price.
View analysts price targets for CHE or view top-rated stocks among Wall Street analysts.

Chemed's stock was trading at $510.43 at the start of the year. Since then, CHE stock has increased by 3.7% and is now trading at $529.27.
View the best growth stocks for 2023 here.

Chemed saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 432,300 shares, a decline of 15.6% from the February 28th total of 512,000 shares. Based on an average daily volume of 73,600 shares, the days-to-cover ratio is presently 5.9 days. Approximately 3.0% of the company's stock are sold short.
View Chemed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our CHE earnings forecast.

Chemed Co. (NYSE:CHE) announced its quarterly earnings data on Friday, February, 24th. The company reported $5.39 EPS for the quarter, beating the consensus estimate of $5.30 by $0.09. The business had revenue of $546.65 million for the quarter, compared to the consensus estimate of $546.60 million. Chemed had a net margin of 11.69% and a trailing twelve-month return on equity of 41.54%. The company's quarterly revenue was up 1.0% compared to the same quarter last year. During the same period last year, the company posted $5.25 earnings per share.

Chemed declared a quarterly dividend on Friday, February 17th. Stockholders of record on Monday, February 27th will be paid a dividend of $0.38 per share on Friday, March 17th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date is Friday, February 24th.
Read our dividend analysis for CHE.

ETFs with the largest weight of Chemed (NYSE:CHE) stock in their portfolio include VictoryShares THB Mid Cap ESG ETF (MDCP), First Trust Dorsey Wright Momentum & Low Volatility ETF (DVOL), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ), Inspire Faithward Mid Cap Momentum ETF (GLRY), Opus Small Cap Value Plus ETF (OSCV), Dividend Performers ETF (IPDP), FIS Biblically Responsible Risk Managed ETF (PRAY) and Natixis Vaughan Nelson Select ETF (VNSE).

Chemed (NYSE:CHE) pays an annual dividend of $1.52 per share and currently has a dividend yield of 0.30%. The company has been increasing its dividend for 14 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 9.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHE will have a dividend payout ratio of 6.73% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CHE.

Chemed updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of $20.75-$21.10 for the period, compared to the consensus EPS estimate of $20.21. The company issued revenue guidance of $2.24 billion-$2.25 billion, compared to the consensus revenue estimate of $2.21 billion.

1 employees have rated Chemed Chief Executive Officer Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among the company's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by a number of institutional and retail investors. Top institutional investors include Neuberger Berman Group LLC (3.62%), William Blair Investment Management LLC (3.37%), Morgan Stanley (2.44%), Geode Capital Management LLC (1.68%), JPMorgan Chase & Co. (1.65%) and Victory Capital Management Inc. (1.54%). Insiders that own company stock include David Patrick Williams, Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends.

Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHE stock can currently be purchased for approximately $529.27.

Chemed (NYSE:CHE) has a market capitalization of $7.91 billion and generates $2.13 billion in revenue each year. The company earns $249.62 million in net income (profit) each year or $16.53 on an earnings per share basis.

The company employs 14,167 workers across the globe.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The official website for the company is www.chemed.com. The company can be reached via phone at (513) 762-6690 or via fax at 513-762-6590.